Trip-Tox Effectiveness of Triptans Before and After Onabotulinumtoxin A Treatment in Chronic Migraine

  • End date
    Sep 25, 2022
  • participants needed
  • sponsor
    Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Updated on 10 October 2021


Observational, longitudinal, prospective, prospective, comparative study of the effectiveness of triptans before and after onabotulintoxin A initiation in a single group of chronic migraine patients.


Hypothesis In patients with chronic migraine the efficacy of triptans, previously taken by the patient for the migraine attack, is better and more satisfactory after starting treatment with onabotulinumtoxinA.

Objectives To analyze the efficacy and satisfaction of the triptan usually taken by the patient with chronic migraine before starting preventive treatment with onabotulinumtoxinA, at 4 months, after two sessions of Botox, and at 7 months of treatment, after three sessions of Botox.

Sample size n=100 patients with chronic migraine in whom treatment with onabotulinumtoxinA is indicated. The indication for Botox treatment will be performed as usual and the patient will take his usual triptan if he has a migraine attack, so there is no therapeutic modification in this study that could involve any bioethical issue.

All patients signed the informed consent and the study was approved by the Comit d'tica de la Investigaci amb Medicaments (CEIm) de l'Hospital de la Santa Creu i Sant Pau.

Condition Chronic Migraine
Treatment OnabotulinumtoxinA
Clinical Study IdentifierNCT04871152
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Last Modified on10 October 2021


Yes No Not Sure

Inclusion Criteria

ICHD-3 criteria for chronic migraine (code 1.3). See Table 3
Older than 18 years and younger than 65 years
Migraine started in their lifetime before the age of 50 years
Migraine of more than one year of evolution since diagnosis
Normal cranial CT/MRI study
Indication for treatment with Botox
Taking triptans as a rescue treatment for migraine attacks

Exclusion Criteria

Pregnant women
Migraine of less than one year of evolution since diagnosis
Pathologies that contraindicate the use of OnabotulinumtoxinA (myasthenia gravis, myopathies)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note